Drug Trial Radar · NCT06871761
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
393
Actual
Start
May 8, 2024
Primary completion
May 13, 2025
Study completion May 13, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events.
Conditions
- Adult Patients With Type 2 Diabetes
Interventions
HR17031 injectionDrug
HR17031 injection
insulin glargineDrug
insulin glargine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in HbA1c from baseline to week 26Time frame: from baseline to week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.